Drug Trial Radar · NCT07061925
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Apr 23, 2025
Primary completion
Nov 21, 2025
Study completion Nov 26, 2025
Sponsor
- Lead sponsor
- Korea Arlico Pharm. Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis
Conditions
- Acute Bronchitis
Interventions
ALC-2203-1Drug
This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
ALC-2203-2Drug
This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
ALC-2203-ACDrug
This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.
PlacaboDrug
This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Bronchitis Severity Score (BSS) at Day 7Time frame: Baseline (Day 0) to Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Konkuk University Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.